Promoter Anand Sureshbhai Desai has pledged 2,00,000 equity shares of Anupam Rasayan India Limited , representing 0.17% of the company's total share capital. The pledge was created on August 6, 2026, and disclosed to stock exchanges on August 14, 2026.

The encumbrance was established to address a shortfall in security cover required for the due payment and discharge of debt arising from the issuance of 16,000 senior, secured, rated, unlisted, and redeemable non-convertible debentures (NCDs). These NCDs carry a nominal value of ₹1,00,000 each, aggregating to ₹160 crore.

Pledge Details

The shares were pledged in favor of Catalyst Trusteeship Limited, acting as the Debenture Trustee for the benefit of Aditya Birla Capital Limited, the holder of the NCDs issued by the company.

Promoter Holding Status

Following this transaction, Anand Sureshbhai Desai's total holding in the company remains 1,10,76,940 shares (9.73%). His encumbered stake increased from 69,75,780 shares (6.13%) to 71,75,780 shares (6.30%).

Other promoters reported no changes in their encumbrance status during this period:

• Mona Anandbhai Desai holds 41,40,625 shares (3.64%), with 26,80,000 shares (2.35%) already encumbered.
• Rehash Industrial and Resins Chemicals Private Limited holds 72,17,040 shares (6.34%), with 50,00,000 shares (4.39%) encumbered.
• Kiran Pallavi Investments LLC holds 3,62,06,896 shares (31.80%), with no encumbered shares.
• Shraddha Anand Desai holds 77,86,435 shares (6.84%), with no encumbered shares.

The disclosure was made under Regulation 31(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Anupam Rasayan India Limited filed its unaudited financial results for the quarter ended June 30, 2026 with the Bombay Stock Exchange on August 15, 2026. The submission was made by Ashish Gupta, Company Secretary & Compliance Officer, pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company confirmed that newspaper advertisements pertaining to the standalone and consolidated unaudited financial results were published in today’s edition of “Financial Express” (English) and “Dhabkar” (Gujarati). These advertisements include a Quick Response code and a weblink to access the complete financial results.

Further, the information is hosted on the company’s website at www.anupamrasayan.com .

Financial Performance Highlights

On a standalone basis, revenue grew by 4% year-on-year to ₹3,349 million (including other income), compared to ₹3,205 million in Q1FY26. Standalone EBITDA rose 17% to ₹1,155 million, with margins expanding to 34% from 31% in the prior year. Standalone PAT increased 8% to ₹320 million, up from ₹297 million. Basic earnings per share on a standalone basis were reported at ₹2.81, compared to ₹2.70 in the corresponding quarter last year.

Strategic Developments and Operational Milestones

During the quarter, Anupam Rasayan achieved a key technological milestone by becoming the first company in the world to commercialize Ethyl Trifluoroacetate (ETFA) using flow chemistry. This advancement strengthens its capabilities in complex fluorination processes. The company added 3 new products in Q1FY27, taking its total product portfolio to 125+ products, with an additional 90+ products currently in the pipeline.

Additionally, the proposed acquisition of Bliss GVS Pharma continues to progress as planned following the signing of the definitive agreement. Management expects this transaction to strengthen the pharmaceutical platform through synergies across CDMO capabilities, product development, and access to regulated markets. Bliss GVS Pharma brings a robust pipeline of 62+ molecules over the next two years, with 48+ molecules catering to regulated markets.

Mr. Anand Desai, Managing Director, stated that the strong start to fiscal year 2027 reflects sustained momentum across businesses and continued execution of the strategy to build a globally integrated specialty chemicals and CDMO platform. He highlighted the robust product pipeline and expanding opportunities across Performance Materials and Pharmaceuticals segments as key drivers for future growth.

What the Numbers Show

The revised financial data presents a more favorable profitability picture than initially reported. While earlier estimates suggested an EBITDA margin contraction to 24.8%, the final unaudited results show an expansion to 26.2%. This improvement, coupled with a 6% rise in PAT despite a 36% surge in revenue, suggests effective operational leverage. The inclusion of other income in the EBITDA figure (₹1,749 million) highlights the contribution of non-operating items to overall operating profit metrics, warranting close scrutiny of the underlying operating cash flows versus accounting profits.

Board Appointments and Governance

During its meeting on August 14, 2026, the Board of Directors approved the unaudited financial results for both standalone and consolidated entities. The board also appointed Mr. Ravi Desai as Chief Operating Officer, effective immediately, while he continues to serve as a Key Managerial Personnel.

The unaudited interim results were reviewed by Natvarlal Vepari & Co., Chartered Accountants, Surat, in accordance with Standard on Review Engagements (SRE) 2410. The consolidated results include subsidiaries such as Jainam Intermediates Private Limited and Tanfac Industries Limited, as well as associate Tangent Science Private Limited.